Pfizer announced Tuesday it is moving forward with the final phase of clinical trials for its COVID-19 vaccine, meaning kids as young as five are one step closer to being able to be vaccinated. Pfizer's new study of more than 4,500 children in four countries, including the United States, will see children ages 11 and under receive a smaller dose of the COVID-19 vaccine than adults.